| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/27/2009 | CA2430696C Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
| 01/27/2009 | CA2416403C A medicinal aerosol formulation |
| 01/27/2009 | CA2415442C Novel .beta. crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same |
| 01/27/2009 | CA2389280C Triazoles as farnesyl transferase inhibitors |
| 01/27/2009 | CA2377126C Thiazole and oxazole derivatives and their pharmaceutical use |
| 01/27/2009 | CA2360248C Combinations of formoterol and a tiotropium salt |
| 01/27/2009 | CA2355243C Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives |
| 01/27/2009 | CA2335115C Fused azepinone cyclin dependent kinase inhibitors |
| 01/27/2009 | CA2332038C Novel pharmaceutical composition for use in emergency treatment and preparation method thereof |
| 01/27/2009 | CA2322633C An iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency, a process for producing said iron-dextran compound and use of said compound for the preparation of a parenterally administrable therapeutical composition |
| 01/27/2009 | CA2283071C Serine proteinase inhibitory activity by hydrophobic tetracycline |
| 01/27/2009 | CA2197319C Lipid analogs for treating viral infections |
| 01/27/2009 | CA2196339C Dna sequences coding for the human proteins tx and ty related to the interleukin-1beta converting enzyme |
| 01/27/2009 | CA2173846C Cntf family antagonists |
| 01/22/2009 | WO2009011336A1 Quinoline compounds |
| 01/22/2009 | WO2009011285A1 Heteroarylbenzene compounds |
| 01/22/2009 | WO2008079834A3 Preparation of paramagnetic nanoparticles conjugated to leukotriene b4 (ltb4) receptor antagonists, and their use as mri contrast agents for the detection of infection and inflammation |
| 01/22/2009 | US20090023900 Anti-AlphaVBeta3 Recombinant Human Antibodies, Nucleic Acids Encoding Same |
| 01/22/2009 | US20090023896 Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds |
| 01/22/2009 | US20090023800 Cannabinoid receptor modulator |
| 01/22/2009 | US20090023791 PH-dependent NMDA receptor antagonists |
| 01/22/2009 | US20090023776 Farnesyl protein transferase inhibitor combinations with antiestrogen agents |
| 01/22/2009 | US20090023770 1-methoxy-2-methyl-3-[(4-nitrophenyl)sulphonyl]indolizine, used as angiogenesis inhibitors |
| 01/22/2009 | US20090023739 Capase inhibitors and uses thereof |
| 01/22/2009 | US20090023722 Amide substituted imidazoquinolines |
| 01/22/2009 | US20090023690 Oral drug delivery system |
| 01/22/2009 | US20090023676 RNA Interference Mediated Inhibition of MAP Kinase Gene Expression or Expression of Genes Involved in MAP Kinase Pathway Using Short Interfering Nucleic Acid (SiNA) |
| 01/22/2009 | US20090023675 RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) |
| 01/22/2009 | US20090023671 Rnai Agents for Maintenance of Stem Cells |
| 01/22/2009 | US20090023659 Using cell surface adhesion proteins specific immunoglobulin to target therapeutics to tumorous; immunodiagnostics; immunotherapy |
| 01/22/2009 | US20090023653 Method of using broad-spectrum delta-endotoxins |
| 01/22/2009 | US20090023649 for treating diseases relating to angiogenesis; fusion protein possesses ribosome inactivating activity and ability to bind to cellular vascular endothelial growth factor (VEGF) receptors |
| 01/22/2009 | US20090023648 Methods for Treating Body Tissue |
| 01/22/2009 | US20090023632 Hemoglobin-haptoglobin complexes |
| 01/22/2009 | US20090023224 Vascular endothelial growth factor 2 |
| 01/22/2009 | US20090023216 Double-Stranded Oligonucleotides |
| 01/22/2009 | US20090022829 lubricant additive to enhance the staying power for male erectile function, comprising Dyclonine, Nitroglycerin, Yohimbine, Herba Asari, Radix Stephaniae Tetrandrae, Rhizoma Corydalis, Azone, Prostaglandin E1, Phentolamine; lubricant coating for condom |
| 01/22/2009 | US20090022815 Halogenated composition, method for preparing same and uses thereof |
| 01/22/2009 | US20090022813 Composition for improving membrane composition and functioning of cells |
| 01/22/2009 | US20090022805 Polypeptide microparticles having sustained release characteristics, methods and uses |
| 01/22/2009 | US20090022797 Stabilized tolterodine tartrate formulations |
| 01/22/2009 | US20090022780 Hydrogel |
| 01/22/2009 | US20090022777 Methods for progenitor cell recruitment and isolation |
| 01/22/2009 | US20090022772 Bioabsorbable elastomeric arterial support device and methods of use |
| 01/22/2009 | US20090022757 Method for treating photoreceptor cell degeneration |
| 01/22/2009 | US20090022744 Modified Fc molecules |
| 01/22/2009 | US20090022739 MODULATING THE KV1.1 VOLTAGE-GATED POTASSIUM CHANNEL IN T-CELLS FOR REGULATING THE SYNTHESIS AND SECRETION OF TUMOR NECROSIS FACTOR ALPHA (tnf-ALPHA) AND TREATING HUMAN DISEASE OR INJURIES MEDIATED BY DETRIMENTALLY HIGH OR LOW LEVELS OF TNF-ALPHA |
| 01/22/2009 | US20090022737 Aldos as modifiers of the igf pathway and methods of use |
| 01/22/2009 | US20090022730 Methods and compositions for assessing acute rejection |
| 01/22/2009 | US20090022724 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 01/22/2009 | US20090022696 Methods for immortalizing cells |
| 01/22/2009 | US20090022693 Method forisolating stem cells from cryopreserved dental tissue |
| 01/22/2009 | US20090022673 Composition and packaging method for animal dental care |
| 01/22/2009 | US20090022669 Compositions for protein delivery via the pulmonary route |
| 01/22/2009 | US20090022666 Methods and systems relating to mitochondrial DNA information |
| 01/21/2009 | EP2017341A2 Apo-2 ligand |
| 01/21/2009 | EP2017283A1 Peptide |
| 01/21/2009 | EP2017281A1 Toll-like receptor 9 agonists |
| 01/21/2009 | EP2017279A1 Novel aminopyridine derivative having aurora-a-selective inhibitory activity |
| 01/21/2009 | EP2017278A1 Dihydropyrazolopyrimidinone derivative |
| 01/21/2009 | EP2017275A1 Benzisoxazole compound |
| 01/21/2009 | EP2017263A1 Heteroarylamide lower carboxylic acid derivative |
| 01/21/2009 | EP2016953A2 Vascular endothelial cell growth factor antagonists and uses thereof |
| 01/21/2009 | EP2016944A2 Angiogenesis inhibitor containing a derivative of rifampicin |
| 01/21/2009 | EP2016942A1 Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders |
| 01/21/2009 | EP2016080A1 Dihydropyrazolopyrimidinone derivatives |
| 01/21/2009 | EP1483375B1 A method for producing recombinant adenovirus viruses using site-specific recombination |
| 01/21/2009 | EP1444211B1 Quinazoline derivatives as antitumor agents |
| 01/21/2009 | EP1127107B1 Methods for the production of tcr gamma delta t cells |
| 01/21/2009 | EP0993468B1 Compositions and methods for activating genes of interest |
| 01/21/2009 | EP0975760B1 Motilin homologs |
| 01/21/2009 | EP0951466B1 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
| 01/21/2009 | CN101351453A 杂环酰胺化合物及其用途 The heterocyclic amide compounds and use thereof |
| 01/21/2009 | CN101348812A Lichenin, and preparation and use thereof |
| 01/21/2009 | CN101348526A Anti-interleukin-8 antibody |
| 01/21/2009 | CN101348524A Protein stabilization formulations |
| 01/21/2009 | CN101348467A Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 01/21/2009 | CN101347540A Medical ointment for treating cheimaphobia |
| 01/21/2009 | CN101347431A Use of flibanserin in the treatment of sexual disorders |
| 01/21/2009 | CN101347254A Qi-benefitting blood-tonifying drink and method for producing the same |
| 01/21/2009 | CN101347105A Method for using garlic in large scale ecological nursing short necked clam |
| 01/21/2009 | CN100453549C 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 01/21/2009 | CN100453547C Inhibitors |
| 01/21/2009 | CN100453530C Compounds and methods for inhibition of expression of VCAM-1 |
| 01/21/2009 | CN100453066C Drug delivery system using subconjunctival depot |
| 01/21/2009 | CN100452984C Aimal growth regulating composition and its prepn and use |
| 01/20/2009 | US7479564 e.g. 6-ethyl-5-(4-{2-[({[(4-methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-5H-[1,3]dioxolo[4,5-f]benzimidazole; prostaglandin E2 receptor antagonists; arthritis, hyperalgesia, uterine contraction, digestive peristalsis, awakeness, blood pressure, platelet function, bone metabolism, angiogenesis |
| 01/20/2009 | US7479563 Method of producing polymorphic crystals of donepezil hydrochloride |
| 01/20/2009 | US7479541 and fusion proteins with green fluorescent protein, used for modulating cell differentiation and apoptosis, including cell formation of tissues |
| 01/20/2009 | US7479539 Hedgehog fusion proteins |
| 01/20/2009 | US7479501 Heteroaryl-cyclic acetals |
| 01/20/2009 | US7479499 Methods of using thalidomide in combination with irinotecan |
| 01/20/2009 | US7479497 e.g. 8-hydroxy-2-[2-[3,4-dihydroxy-5-methoxyphenyl)ethenyl]]-7-quinoline carboxylic acid; HIV integrase inhibitors; AIDS, retroviral pathologies |
| 01/20/2009 | US7479492 Use combined 5-HT1A agonists and selective serotonin reuptake inhibitors |
| 01/20/2009 | US7479485 Method of treating arrhythmias |
| 01/20/2009 | US7479287 Methods of inhibiting proliferation of cells |
| 01/20/2009 | CA2502856C Intermediates for retroviral protease inhibiting compounds |
| 01/20/2009 | CA2477839C Nitrogen containing heterocyclic compounds and medicines containing the same |
| 01/20/2009 | CA2465871C Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1 |
| 01/20/2009 | CA2465738C Unsaturated 1-amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists |